CACarlos Aude

Carlos Aude

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carlos Aude has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Ruth Bass

    Hospital for Special Surgery and Weill Cornell Medicine New York New York

    5 shared publications
  • Karmela Kim Chan

    K.K. Chan, MD, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, New York, USA; Division of Rheumatology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA

    3 shared publications
  • Nilasha Ghosh

    Division of Rheumatology, Hospital for Special Surgery and Weill Cornell Medicine, New York, New York, USA

    3 shared publications
  • Vikas N. Vattipally

    Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland

    3 shared publications
  • Chetan Bettegowda

    Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA

    2 shared publications
  • Debraj Mukherjee

    Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA

    2 shared publications

Latest Publications

  • Objective Pupillometry and Dexterity Assessment in Surgical Trainees: A Pilot Study

    by Patrick Kramer, Kelly Jiang, Carly Weber-Levine, Roger D. Soberanis-Mukul, Jose L. Porras, Vikas N. Vattipally, Farzad Maroufi, A. Daniel Davidar, Claire Hao, Mustafa Najeed, et al.

  • Open Access

    Arthroplasty Joint Histology and Surgical Outcomes in Patients on Immune Checkpoint Inhibitors: A Single-Center Case Series

    by Karmela K. Chan, Nilasha Ghosh, Carlos Aude, Edward DiCarlo, Anne R. Bass

    Plain Language Summary This is a case series of 16 patients with cancer who were treated with immune checkpoint inhibitor (ICI) therapy and who underwent 23 joint replacements. Some of these patients were known to have inflammatory arthritis (joint inflammation) as a side effect of the ICI therapy, whereas others were thought to have worsening of established osteoarthritis (OA). We wanted to know whether the patients with OA had ICI-related joint inflammation that was simply not recognized before surgery. We also wanted to know whether patients who undergo joint replacements on ICI have more surgery complications than other people. What we found was that the people who were diagnosed with OA prior to surgery had OA on joint histology. Only the patients with known inflammatory arthritis from ICI had significant inflammation on joint histology. One patient required a revision of her hip joint replacement 3.7 years after surgery (while still on ICI) due to an inflammatory reaction to her joint replacement. We could not determine whether ICI played a role in that complication.


  • Machine Learning Reveals Demographic Disparities in Palliative Care Timing Among Patients With Traumatic Brain Injury Receiving Neurosurgical Consultation

    by Carlos A. Aude, Vikas N. Vattipally, Oishika Das, Kathleen R. Ran, Ganiat A. Giwa, Jordina Rincon-Torroella, Risheng Xu, James P. Byrne, Susanne Muehlschlegel, Jose I. Suarez, et al.

    Background Timely palliative care (PC) consultations offer demonstrable benefits for patients with traumatic brain injury (TBI), yet their implementation remains inconsistent. This study employs machine learning methods to identify distinct patient phenotypes and elucidate the primary drivers of PC consultation timing variability in TBI management, aiming to uncover disparities and inform more equitable care strategies. Methods Data on admission, hospital course, and outcomes were collected for a cohort of 232 patients with TBI who received both PC consultations and neurosurgical consultations during the same hospitalization. Patient phenotypes were uncovered using principal component analysis and K-means clustering; time-to-PC consultation for each phenotype was subsequently compared by Kaplan–Meier analysis. An extreme gradient boosting model with Shapley Additive Explanations identified key factors influencing PC consultation timing. Results Three distinct patient clusters emerged: cluster A (n = 86), comprising older adult White women (median 87 years) with mild TBI, received the earliest PC consultations (median 2.5 days); cluster B (n = 108), older adult White men (median 81 years) with mild TBI, experienced delayed PC consultations (median 5.0 days); and cluster C (n = 38), middle-aged (median: 46.5 years), severely injured, non-White patients, had the latest PC consultations (median 9.0 days). The clusters did not differ by discharge disposition (p = 0.4) or inpatient mortality (p > 0.9); however, Kaplan–Meier analysis revealed a significant difference in time-to-PC consultation (p < 0.001), despite no differences in time-to-mortality (p = 0.18). Shapley Additive Explanations analysis of the extreme gradient boosting model identified age, sex, and race as the most influential drivers of PC consultation timing. Conclusions This study unveils crucial disparities in PC consultation timing for patients with TBI, primarily driven by demographic factors rather than clinical presentation or injury characteristics. The identification of distinct patient phenotypes and quantification of factors influencing PC consultation timing provide a foundation for developing for standardized protocols and decision support tools to ensure timely and equitable palliative care access for patients with TBI.


  • Open Access

    Temporal Trends in the Rate of Revision Total Knee Arthroplasty for Prosthetic Joint Infection

    by Anne R. Bass, Bella Mehta, Peter K. Sculco, Yi Zhang, Huong T. Do, Katharine Kayla J. Glaser, Carlos Aude, Alberto V. Carli, Mark P. Figgie, Susan M. Goodman


  • Open Access

    Machine Learning Identifies Variation in Timing of Palliative Care Consultations Among Traumatic Brain Injury Patients

    by Carlos A. Aude, Vikas N. Vattipally, Oishika Das, Kathleen R. Ran, Ganiat A. Giwa, Jordina Rincon-Torroella, Risheng Xu, James P. Byrne, Susanne Muehlschlegel, Jose I. Suarez, et al.

    Background and Objective Timely palliative care involvement offers demonstrable benefits for traumatic brain injury (TBI) patients; however, palliative care consultations (PCCs) are used inconsistently during TBI management. This study aimed to employ advanced machine learning techniques to elucidate the primary drivers of PCC timing variability for TBI patients. Methods Data on admission, hospital course, and outcomes were collected for a cohort of 232 TBI patients who received both PCCs and neurosurgical consultations during the same hospitalization. Principal Component Analysis (PCA) and K-means clustering were used to identify patient phenotypes, which were then compared using Kaplan-Meier analysis. An extreme gradient boosting model (XGBoost) was employed to determine drivers of PCC timing, with model interpretation performed using SHapley Additive exPlanations (SHAP). Results Cluster A (n = 86) consisted mainly of older (median [IQR] = 87 [78, 94] years), White females with mild TBIs and demonstrated the shortest time-to-PCC (2.5 [1.0, 7.0] days). Cluster B (n = 108) also sustained mild TBIs but comprised moderately younger (81 [75, 86] years) married White males with later PCC (5.0 [3.0, 10.8] days). Cluster C (n = 38) represented much younger (46.5 [29.5, 59.8] years), more severely injured, non-White patients with the latest PCC initiation (9.0 [4.2, 17.0] days). The clusters did not differ by discharge disposition (p = 0.4) or frequency inpatient mortality (p > 0.9); however, Kaplan-Meier analysis revealed a significant difference in the time from admission to PCC (p < 0.001), despite no differences in time from admission to mortality (p = 0.18). SHAP analysis of the XGBoost model identified age, sex, and race as the most influential drivers of PCC timing. Conclusions This study highlights crucial disparities in PCC timing for TBI patients and underscores the need for targeted strategies to ensure timely and equitable palliative care integration for this vulnerable population.


  • Clonally expanded CD38 hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis

    by Runci Wang, Anvita Singaraju, Kathryne E. Marks, Lorien Shakib, Garrett Dunlap, Ifeoluwakiisi Adejoorin, Stinne R. Greisen, Lin Chen, Aidan K. Tirpack, Carlos Aude, et al.

    Immune checkpoint inhibitor (ICI) therapies used to treat cancer, such as anti–PD-1 antibodies, can induce autoimmune conditions in some individuals. The T cell mechanisms mediating such iatrogenic autoimmunity and their overlap with spontaneous autoimmune diseases remain unclear. Here, we compared T cells from the joints of 20 patients with an inflammatory arthritis induced by ICI therapy (ICI-arthritis) with two archetypal autoimmune arthritides, rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Single-cell transcriptomic and antigen receptor repertoire analyses highlighted clonal expansion of an activated effector CD8 T cell population in the joints and blood of patients with ICI-arthritis. These cells were identified as CD38 hi CD127 − CD8 T cells and were uniquely enriched in ICI-arthritis joints compared with RA and PsA and also displayed an elevated interferon signature. In vitro, type I interferon induced CD8 T cells to acquire the ICI-associated CD38 hi phenotype and enhanced cytotoxic function. In a cohort of patients with advanced melanoma, ICI therapy markedly expanded circulating CD38 hi CD127 − T cells, which were frequently bound by the therapeutic anti–PD-1 drug. In patients with ICI-arthritis, drug-bound CD8 T cells in circulation showed marked clonal overlap with drug-bound CD8 T cells from synovial fluid. These results suggest that ICI therapy directly targets CD8 T cells in patients who develop ICI-arthritis and induces an autoimmune pathology that is distinct from prototypical spontaneous autoimmune arthritides.


  • Open Access

    Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 ‘shared epitope’ are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis

    by Nilasha Ghosh, Pankti Reid, Carlos Andres Aude, Jessica Kirschman, Susan Goodman, Vivian P Bykerk, Amit Lakhanpal, Diviya Rajesh, Karmela K Chan, William H Robinson, et al.

    Background Immune checkpoint inhibitors (ICI) can potentially cause ICI-inflammatory arthritis (ICI-IA), which often resembles rheumatoid arthritis (RA). In this study, we examined the degree of anticitrullinated peptide antibodies (ACPA) epitope expansion in CCP+ICI-IA and patients with RA. Methods We used clinical data and serum from ICI-IA and patients with RA with early disease as well as longstanding disease. A custom, bead-based antigen array was used to identify IgG ACPA reactivities to 18 putative RA-associated citrullinated proteins. Hierarchical clustering software was used to create a heatmap to identify ACPA levels. Additionally, HLA DRB1 typing was performed on ICI-IA patients as well as controls of patients treated with ICI that did not develop ICI-IA (ICI controls). Results Compared to patients with CCP+RA, patients with CCP+ICI-IA were older (pConclusion Patients with ICI-IA had lower ACPA titres and targeted fewer ACPA epitopes than longstanding patients with RA, and there were no significant differences in the presence of the shared epitope between those that developed ICI-IA and ICI controls. It remains to be determined if ICI-IA represents an accelerated model of RA pathogenesis with ICI triggering a transition from preclinical to clinical disease.


  • Top Cited Papers

    Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis

    by Anne R Bass, Noha Abdel-Wahab, Pankti D Reid, Jeffrey A Sparks, Cassandra Calabrese, Deanna P Jannat-Khah, Nilasha Ghosh, Divya Rajesh, Carlos Andres Aude, Lydia Gedmintas, et al.

    Objectives To compare the safety and effectiveness of biologic and conventional disease-modifying antirheumatic drugs (DMARDs) for immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA). Methods The retrospective multicentre observational study included patients with a diagnosis of ICI-IA treated with a tumour necrosis factor inhibitor (TNFi), interleukin-6 receptor inhibitor (IL6Ri) and/or methotrexate (MTX); patients with pre-existing autoimmune disease were excluded. The primary outcome was time to cancer progression from ICI initiation; the secondary outcome was time to arthritis control from DMARD initiation. Cox proportional hazard models were used to compare medication groups, adjusting for confounders. Results 147 patients were included (mean age 60.3 (SD 11.9) years, 66 (45%) women). ICI-IA treatment was TNFi in 33 (22%), IL6Ri 42 (29%) and MTX 72 (49%). After adjustment for time from ICI initiation to DMARD initiation, time to cancer progression was significantly shorter for TNFi compared with MTX (HR 3.27 (95% CI 1.21 to 8.84, p=0.019)) while the result for IL6Ri was HR 2.37 (95% CI 0.94 to 5.98, p=0.055). Time to arthritis control was faster for TNFi compared with MTX (HR 1.91 (95% CI 1.06 to 3.45, p=0.032)) while the result for IL6Ri was HR 1.66 (95% CI 0.93 to 2.97, p=0.089). A subset analysis in patients with melanoma gave similar results for both cancer progression and arthritis control. Conclusion The treatment of ICI-IA with a biologic DMARD is associated with more rapid arthritis control than with MTX, but may be associated with a shorter time to cancer progression.